Showing 119 of 119on this page. Filters & sort apply to loaded results; URL updates for sharing.119 of 119 on this page
Agência Europeia de Medicamentos (EMA) valida os registros da Henlius e ...
Henlius 2022 H1 Results: Sharpen all-round edges, advance in evolution ...
FAST NEWS: Henlius swings to the black on strong sales growth - Bamboo ...
Henlius claims win for PD-1 drug in small cell lung cancer | pharmaphorum
Henlius Biotech Prices Hong Kong IPO to Raise $477 Million | NAI 500
Henlius Shines at World ADC Asia 2024, Showcasing Its Innovative R&D ...
Henlius Forecasts Profit in 2023 H1: Spurring a Seamless R&D ...
FAST NEWS: Henlius Biotech’s revenue doubles in first quarter - Bamboo ...
Henlius and Organon Receive the US FDA’s Approval for Bildyos ...
Henlius and Organon Enter into a License and Supply Agreement for ...
Henlius finds elixir in first profits, scraps A-share IPO - Bamboo ...
Henlius Trastuzumab Receives FDA Approval in the United States-Media
Henlius Biotech Reports 6.1% Revenue Growth with Strong Oncology ...
Live Webcast | Henlius to Present at JPM 2026, Outlining Its ...
Henlius Showcases HLX3902 Preclinical Data at AACR 2026, Highlighting ...
Henlius Trastuzumab receives FDA approval in the United States
Henlius Expands Collaboration with KGbio to Develop, Commercialize and ...
Henlius 2025 Annual Results Showcase Unprecedented Revenue and Profit ...
Henlius Wins EU Approval for Two New Serplulimab Cancer Uses - TipRanks.com
Henlius Receives "Listed Enterprises 2023" Award from Bloomberg ...
Henlius 2021 Annual Results: New Record in Performance, Evolving to ...
Henlius Unveils Strategic Innovation Plans at JPM Healthcare ...
Watch Henlius Aims to Launch More Biosimilars in US, EU - Bloomberg
Henlius Showcases Innovations and Strengthens International ...
Henlius Recognized as 2024 Forbes China Go-International Series Top 30 ...
Henlius 2023 Annual Results: Revenue surpassed RMB5.39 billion with a ...
Henlius Forecasts Profit in 2023: Achieving first full year of ...
Henlius Reported Financial Results for the First Three Quarters of 2023 ...
Henlius Wins U.S. FDA IND Nod for Multiple Myeloma Biosimilar HLX15-SC ...
Henlius Biotech holds R&D day in Shanghai - Chinadaily.com.cn
Henlius Announces Successful Completion of Phase 1 Clinical Study of ...
Henlius Biotech's HLX22 Receives Clinical Trial Approval in Germany for ...
Henlius Holds its first Scientific Advisory Board Meeting of 2024-Media
Henlius and Sandoz Enter a Global Collaboration Agreement to ...
HENLIUS reaches a record high, with multiple innovative pipelines to be ...
Henlius Biotech Expands Partnership with Palleon Pharmaceuticals for ...
Henlius
Henlius Biosimilar for Breast Cancer Gets FDA Approval | Henlius posted ...
Henlius HANBEITAI - Bevacizumab Injection By Shanghai Henlius Biotech, Inc
Henlius Biotech Joins Biosimilars Forum to Expand Global Biosimilars ...
Shanghai Henlius Biotech Secures FDA IND Approval for HLX17, a ...
Henlius Holds its 1st Overseas Scientific Advisory Board Meeting of ...
Henlius Presents Four Hanjugator™ ADCs at AACR 2026, with Multiple ...
Henlius Passes Its Second EU GMP Inspection-Media
Henlius Deepens Collaboration with Intas to bring Henlius’ Novel anti ...
Henlius Biotech Initiates Phase III Study for HLX22 in Gastric Cancer ...
First Shipment of Henlius Trastuzumab to U.S.-Media
Henlius Trastuzumab Receives FDA Approval in the United States - YouTube
Henlius and Convalife Reach Global Strategic Cooperation on Neratinib-Media
Henlius and Sermonix Announce Strategic Collaboration and Exclusive ...
Henlius Wins Japan Go-Ahead for Global Phase 2/3 Trial of Lung Cancer ...
Henlius Biotech Initiates US Commercial Supply of Hanquyou, Biosimilar ...
Shanghai Henlius and Alvogen Korea Ink Licensing Deal for HanSiZhuang ...
Henlius Wins Generics Bulletin ‘Business Development of the Year’ Award ...
Henlius Biotech shareholders reject take-private offer from China's ...
Henlius Shines for Five Consecutive Years at BIO International ...
Henlius Biotech Starts Global Phase II Trial for PD-L1 ADC HLX43 ...
HanchorBio Out-Licenses HCB101 to Shanghai Henlius Biotech For ~$202M ...
Henlius Biotech shrugs off Hong Kong disruption with $477M IPO bid ...
Henlius and SVAX Forge Strategic Partnership in the MENAT Market-Media
Another Look: Shanghai Henlius Shares Hit A Near Five-Year High
Henlius Biotech Doses First Patient in Japanese Bridging Trial of ...
Shanghai Henlius Biotech 2025 Annual Report: Global Expansion, Product ...
Hong Kong-listed biotech firm Henlius edges closer to Star Market ...
Henlius 2023 H1 Results: Achieved record profits and RMB2.5 billion ...
FAST NEWS: Henlius expects first-ever annual profit on strong drug ...
Henlius to Release Clinical Data at 2024 ASCO GI-Media
Henlius Attends BIO 2022-Media
What is Brief History of Shanghai Henlius Biotech Company ...
Shanghai Henlius Biotech's HLX22 Receives NMPA Approval for Phase II ...
Shanghai Henlius Biotech Earns GMP Certification for Prolia/Xgeva ...
Henlius Biotech
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab ...
Shanghai Henlius Biotech Expands Collaboration with KGbio Genexine ...
European Medicines Agency (EMA) Validates Henlius and Organon Filing ...
Henlius Partners with Getz to commercialize Adalimumab Biosimilar ...
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech ...
Henlius in-licenses lasofoxifene from Sermonix | The Pharmaletter
Henlius USA Inc. | LinkedIn
Henlius 2025 Global R&D Day: A Summit for Innovation and Strategy in ...
Shanghai Henlius Biotech - Crunchbase Company Profile & Funding
Careers-Corporate Culture
About Henlius-Company Profile
复宏汉霖Henlius
Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the ...
Henlius' HLX43 Approved by FDA for Phase 1 Trial in Thymic Carcinoma ...
Product-Products in R&D
Henlius’ Trastuzumab Approved in Brazil, a Semi-Exclusive License Area ...
Henlius: using a fully integrated platform to advance high-quality ...
About Henlius-Corporate Culture
FDA Approves Shanghai Henlius’s Interchangeable Pertuzumab Biosimilar ...
IMF Chief Economist Visits Henlius: Witnessing China's Economic ...
Results from Four Phase 1/2 Clinical Trials of Henlius’ Innovative ...
Henlius, Organon receive FDA OK for Perjeta biosimilar | Drug Store News
Henlius' revenue in the first half of 2022 increased by 103.5%, and the ...
FDA Approves Henlius’ Trastuzumab Biosimilar, Hercessi
Media-Media Reports
Media-News
Henlius, Organon Gain FDA Nod for First Pertuzumab Biosimilar | OGN ...
Henlius' Strategic Positioning for Long-Term Growth in Global Biopharma ...
Henlius' Strategic Collaborations and Pipeline Momentum Position It as ...
Investor Relations-Information Disclosure
Mr. Jason Zhu Succeeds as Chief Executive Officer and Mr. Wenjie Zhang ...
Inside Henlius' global growth strategy
Henlius' Trastuzumab biosimilar (HLX02) was approved by US FDA on Apr ...
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab ...
Using a fully integrated platform to advance high-quality, affordable ...
